PULMATRIX, INC. (NASDAQ:PULM) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders. |
On June8, 2017, Pulmatrix, Inc. (the Company) held its 2017
annual meeting of stockholders (the Annual Meeting). At the
Annual Meeting, the following two proposals were submitted to the
Companys stockholders:
| (1) |
Election of two directors to serve as ClassIII directors on our Board of Directors to serve until our 2020 Annual Meeting of Stockholders or until successors have been duly elected and qualified, for which the following were nominees: Michael J. Higgins and Mark Iwicki. |
| (2) |
Ratification of the appointment of Marcum LLP as the Companys independent registered public accounting firm for the fiscal year ending December31, 2017. |
For more information about the foregoing proposals, see the
Companys definitive proxy statement for the Annual Meeting, filed
with the Securities and Exchange Commission on April28, 2017, the
relevant portions of which are incorporated herein by reference.
Holders of the Companys common stock were entitled to one vote
per share. The number of votes cast for and against and the
number of abstentions and broker non-votes with respect to each
matter voted upon are set forth below.
| (1) |
Election of two directors to serve as ClassIII directors on our Board of Directors to serve until our 2020 Annual Meeting of Stockholders: |
|
Director |
For | Withheld | BrokerNon-Votes | |||
|
Michael J. Higgins |
7,604,036 | 83,670 | 6,468,918 | |||
|
Mark Iwicki |
7,647,515 | 40,191 | 6,468,918 |
| (2) |
Ratification of the appointment of Marcum LLP as the Companys independent registered public accounting firm for the fiscal year ending December31, 2017: |
|
For |
Against | Abstain | ||
| 13,944,280 | 109,355 | 102,989 |
The results reported above are final voting results. No other
matters were considered or voted upon at the meeting.
About PULMATRIX, INC. (NASDAQ:PULM)
Pulmatrix, Inc. is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis. In addition, the Company focuses on pulmonary diseases through collaboration with partners, including PUR0200, a generic in clinical development for chronic obstructive pulmonary disease.
